Carbamazepine extended-release capsules vs. oxcarbazepine: Computer simulations of the effect of missed doses on drug plasma concentrations

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1363-1368

  Ahmad, Alaa ^a   Garnett, William R ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Carbamazepine; Dosing; Extended; Models; Oxcarbazepine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; OXCARBAZEPINE;

ARTICLE; COMPARTMENT MODEL; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG RELEASE; EPILEPSY; HUMAN; LONG TERM CARE; TREATMENT OUTCOME;

ANTICONVULSANTS; CARBAMAZEPINE; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT COMPLIANCE; UNITED STATES;

EID: 25444468607     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X59120     Document Type: Article

References (18)

1. Leppik IE. Variability of antiepileptic medication concentrations and compliance. In: Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991, pp.349-358
2. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7
3. Garnett WR, Levy B, McLean AM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39:274-9
4. Hoppener RJ, Kuyer A, Meijer JW, et al. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21:341-50
5. Garnett WR, McLean AM, Zhang Y, et al. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin 2003;19:519-25
6. Mirza WU, Rak IW, Thadani VM, et al. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998;51:1727-9
7. Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: An open-label, 12- to 36-month continuation study. Clin Ther 2003;25:2586-96
8. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023-42
9. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6
10. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000;41:107-39
11. Reinikainen KJ, Keranen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284-9
12. McLean A, Browne S, Zhang Y, et al. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J Clin Pharmacol 2001;41:183-6
13. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
14. Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999;33:39-55
15. Begley CE, Lairson DR, Reynolds TF, et al. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 2001;47:205-15
16. Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20:191S-9
17. Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000;41(Suppl 5):S37-44
18. Buck D, Jacoby A, Baker GA, et al. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997;6:87-93